Home > Compound List > Product Information
URB602_Molecular_structure_CAS_565460-15-3)
Click picture or here to close

URB602

Catalog No. U3010 Name Sigma Aldrich
CAS Number 565460-15-3 Website http://www.sigmaaldrich.com
M. F. C19H21NO2 Telephone 1-800-521-8956
M. W. 295.37554 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 130096

SYNONYMS

IUPAC name
cyclohexyl N-(3-phenylphenyl)carbamate
IUPAC Traditional name
cyclohexyl N-(3-phenylphenyl)carbamate
Synonyms
[1,1’-Biphenyl]-3-yl-carbamic acid cyclohexyl ester

DATABASE IDS

MDL Number MFCD08457914
CAS Number 565460-15-3

PROPERTIES

Empirical Formula (Hill Notation) C19H21NO2
Purity ≥98% (HPLC)
Apperance white to off-white powder
Solubility DMSO: >10 mg/mL
MSDS Link Download
Personal Protective Equipment Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
Storage Temperature 2-8°C
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
URB602 is an inhibitor of monoacylglycerol lipase (MGL). The IC50 = 28 μM and Km = 20 μM. URB602 increases 2-arachidonoylglycerol (2-AG) concentrations. When URB602 is injected into the periaqueductal grey matter, it enhances stress-induced analgesia (tail-flick test) in a CB1-dependent manner. An effect that is prevented by a CB1 cannabinoid receptor antagonist, Rimonabant (SR141716). URB602 is not suitable for systemic administration due to relatively low potency, but useful for research of pain and stress-related disorders, which identifies MGL as a previously unrecognized therapeutic target (highlighted in Chemical Engineering News, June 27, 2005).
Description (简体中文)
Biochem/physiol Actions
URB602 is an inhibitor of monoacylglycerol lipase (MGL). The IC50 = 28 μM and Km = 20 μM. URB602 increases 2-arachidonoylglycerol (2-AG) concentrations. When URB602 is injected into the periaqueductal grey matter, it enhances stress-induced analgesia (tail-flick test) in a CB1-dependent manner. An effect that is prevented by a CB1 cannabinoid receptor antagonist, Rimonabant (SR141716). URB602 is not suitable for systemic administration due to relatively low potency, but useful for research of pain and stress-related disorders, which identifies MGL as a previously unrecognized therapeutic target (highlighted in Chemical Engineering News, June 27, 2005).

REFERENCES